As an enzyme replacement therapy (ERT), idursulfase is often prescribed for mucopolysaccharidosis (MPS) II (Hunter syndrome), facilitating the degradation of glycosaminoglycans (GAGs) by replacing the deficient enzyme iduronate-2-sulfatase [14]. This evidence concerns the gene IDS and mucopolysaccharidosis.